Dyadic International (DYAI) Other Operating Expenses (2018 - 2026)
Dyadic International (DYAI) posted Other Operating Expenses of $542240.0 for Q1 2026, up 170.29% sequentially from $200611.0 in Q4 2025, and up 785.52% YoY from $61234.0 in Q1 2025.
Dyadic International (DYAI) Other Operating Expenses (2018 - 2026) Analysis & Trends
Dyadic International has reported Other Operating Expenses for 9 years, with the latest figure at $542240.0 in Q1 2026.
- Quarterly Other Operating Expenses rose 785.52% year-over-year to $542240.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 401.21% YoY) and the FY2025 annual result came in at $1.5 million, up 566.16% from the prior year.
- Other Operating Expenses advanced to $542240.0 in Q1 2026 per DYAI's latest filing, from $200611.0 in the prior quarter.
- Over five years, Other Operating Expenses peaked at $1.3 million in Q4 2022 and troughed at -$107940.0 in Q1 2024.
- A 5-year average of $412465.8 and a median of $378310.0 in 2025 frame the typical range for Other Operating Expenses.
- The sharpest annual moves came in 2024 and 2025: Other Operating Expenses sank 114.63% in 2024, then soared 18572.75% in 2025.
- Over 5 years, Other Operating Expenses stood at $1.3 million in 2022, then tumbled by 73.35% to $350392.0 in 2023, then tumbled by 58.76% to $144513.0 in 2024, then jumped by 38.82% to $200611.0 in 2025, then surged by 170.29% to $542240.0 in 2026.
- According to Business Quant data, Other Operating Expenses over the past three periods registered $542240.0, $200611.0, and $836593.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 542,240.00 |
| Dec 31, 2025 | 200,611.00 |
| Sep 30, 2025 | 836,593.00 |
| Jun 30, 2025 | 378,310.00 |
| Mar 31, 2025 | 61,234.00 |
| Dec 31, 2024 | 144,513.00 |
| Sep 30, 2024 | 182,835.00 |
| Jun 30, 2024 | 2,026.00 |
| Mar 31, 2024 | -107,940.00 |
| Dec 31, 2023 | 350,392.00 |
| Sep 30, 2023 | 118,469.00 |
| Jun 30, 2023 | 807,465.00 |
| Mar 31, 2023 | 737,940.00 |
| Dec 31, 2022 | 1.31 Mn |
| Sep 30, 2022 | 616,052.00 |
| Jun 30, 2022 | 431,730.00 |
| Mar 31, 2022 | 394,498.00 |
| Dec 31, 2021 | 352,441.00 |
| Sep 30, 2021 | 422,546.00 |
| Jun 30, 2021 | -2.21 Bn |